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Abstract Recent findings in mice suggest that it is possible
to reverse certain neurodevelopmental disorders in adults.
Changes in development, previously thought to be irrepa-
rable in adults, were believed to underlie the neurological
and psychiatric phenotypes of a range of common mental
health problems with a clear developmental component. As
a consequence, most researchers have focused their efforts
on understanding the molecular and cellular processes that
alter development with the hope that early intervention
could prevent the emergent pathology. Unexpectedly,
several different animal model studies published recently,
including animal models of autism, suggest that it may be
possible to reverse neurodevelopmental disorders in adults:
Addressing the underlying molecular and cellular deficits in
adults could in several cases dramatically improve the
neurocognitive phenotypes in these animal models. The
findings reviewed here provide hope to millions of
individuals afflicted with a wide range of neurodevelop-
mental disorders, including autism, since they suggest that
it may be possible to treat or even cure them in adults.
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Neurodevelopmental disorders encompass a diverse and
large group of disorders that not only affect developmental
processes, but also include various pathologies that extend
into adulthood. Neuropsychiatric phenotypes, such as
autism, specific learning disabilities, ADHD, intellectual
disability and epilepsy are often associated with this class
of disorders. A plethora of genetic mutations and environ-
mental factors (e.g., infections, immune dysfunction,
intoxication, endocrine and metabolic dysfunction, nutri-
tional factors, trauma, etc.) have been implicated in neuro-
developmental disorders. This review will focus on
neurodevelopmental disorders with a clear genetic origin,
such as tuberous sclerosis (TSC) and neurofibromatosis
type I (NF1); However, the basic principle that adult
intervention may ameliorate or even cure this large class
of diseases may also apply to neurodevelopmental disorders
without an obvious genetic contribution. An earlier version
of this review was previously published [1].
The long-term impact of disrupting neurodevelopmental
processes
There is a considerable amount of evidence suggesting that
alterations in neurogenesis, cell migration, neuronal con-
nectivity and in other developmental processes cause
neurological, psychiatric and cognitive deficits in adults.
For example, changes in the structure of specific brain
regions during development have been suspected to
underlie neurodevelopmental disorders. Development is an
especially vulnerable stage where insults that have only
minor repercussions in adults can cause profound patholo-
gies. For example, mutations leading to phenylketonuria
have serious effects during development, but stopping
treatment results only in mild phenotypes in adults [2].
Similarly, untreated congenital hypothyroidism can lead to
profound and irreversible cognitive deficits, while hypo-
thyroidism in adults has milder effects on cognitive
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function [3–6]. Although development may be an especial-
ly fragile period, there are also examples of manipulations
that result in far more serious effects in adults than in
development. For example, trauma, infection, and ischemia
may have much of the same or even more serious
consequences in adults than during development [7, 8].
Animal studies have also shown that genetic disruptions
with mild or no consequences in adults lead to serious
functional disruptions when these disruptions are carried out
during development, including postnatal development. Re-
cently, a study with a carboxyl terminal end of the disrupted in
schizophrenia 1 (Disc1) gene showed that a brief (6–12 h)
induction of a dominant negative mutant Disc1 allele during
postnatal day 7 of development [9], but not in adults, is
sufficient to trigger many phenotypes relevant for schizo-
phrenia. This included deficits in working memory, social
interaction, depression-like behaviors and neuronal structure
[9], demonstrating that a carboxy-terminal portion of this
protein modulates processes at post-natal day 7 that are
critical for normal behavior in adults.
A carboxy-terminal portion of the Disc1 protein was
regulated by fusing it with a mutant form of the estrogen
ligand binding domain that does not bind estrogen but that
instead binds tamoxifen [9]. The transgenic fusion protein
stays inactive in the cell until tamoxifen is given to the mice
[9]. Tamoxifen binds to the ligand binding domain of the
fusion protein, changes its conformation and excludes heat
shock proteins bound to the ligand binding domain; These
heat shock proteins prevent the transgenic fusion protein
from interfering with binding between Disc1 and its
partners, such as Nudel [9]. Thus, addition of tamoxifen
frees the transgenic carboxy-terminal portion of the Disc1
in the fusion protein to disrupt normal Disc1 function [9].
These results showed that interactions between the carboxy-
terminal portion of Disc1 and other proteins, such as Nudel,
during postnatal development are critical for several
behaviors disrupted in schizophrenia.
Interestingly, there is also evidence that Disc1 in the
adult brain has a role in behavior [10]. Recent findings
suggest that the amino terminal fragment of Disc1 binds to
and regulates Gsk3beta function in the dentate gyrus of
adult mice [10]. Knocking down of Disc1 in mice leads to
hyperlocomotion in response to novelty, and higher
depression-like behaviors in the forced swim test [10].
Importantly, treating the adult Disc1 mutant mice with a
specific chemical inhibitor of Gsk3 (SB-216763) reversed
both the hyperlocomotion and depression-like phenotypes
of these mutants, sugesting that a decrease in Disc1
function in adult mice leads to higher Gsk3 activity and
that this plays a critical role in these interesting behavioral
phenotypes.
In contrast, the studies described above with an inducible
dominant negative Disc1 protein fragment, that disrupted
protein interactions specifically with the carboxy-terminal
portion of Disc1 in the adult brain, did not affect depression-
like behaviors in the forced swim test [9]. However, as stated
above, induction of this dominant negative Disc1 protein
fragment during day 7 of development did affect perfor-
mance in this behavioral model of depression [9]. As
indicated above, the Gsk3 experiments demonstrate that
adult interactions between Gsk3 and the N-terminal portion
of Disc1 are critical for function in this same behavioral
model of depression [9]. This indicates that a gene causing
schizophrenia (Disc1), a neurodevelopmental disorder, has
effects both in development and in adults.
Similar to DISC1, other genes associated with develop-
mental disorders are also expressed in the adult brain. Thus,
beyond any effects on development, disruptions of these
genes in the adult brain may also contribute to phenotypes
observed in adult individuals. A tantalizing possibility is
that the loss of function of these neurodevelopmental genes
may prevent functional recovery in adults, and that rescuing
gene function in adults may allow latent neurodevelopmen-
tal processes to compensate for developmental deficits.
Accordingly, several recent studies with mouse models
demonstrate that adult expression of neurodevelopmental
genes make a significant contribution to cognitive function.
These findings showed that reversing the disruptions in
molecular and cellular function specifically in adults can
result in clear behavioral improvements.
A ray of hope: reversing cognitive deficits in adults
There are now a number of compelling examples, in mice,
of rescue of neurocognitive deficits associated with devel-
opmental disorders in adults, including NF1, TSC, Down
syndrome, Rubinstein-Taybi syndrome (RTS), Fragile X
syndrome (FXS), and Rett syndrome.
Ras-dependent activation of Mitogen Activated Protein
Kinase (MAPK) has a key role in synaptic plasticity as well
as learning and memory, and disruptions in this signaling
pathway underlie a number of genetic disorders that affect
cognitive function. For example, mutations in the Neurofi-
bromatosis type 1 (NF1) gene, encoding neurofibromin, a
p21Ras GTPase Activating Protein (GAP), cause learning
disabilities, including difficulties with visuo-spatial skills,
memory and attentional-executive function deficits. These
neurocognitive phenotypes can be effectively modeled in
mice with a heterozygous null mutation of the Nf1 gene
(Nf1+/−) [11, 12]. Recent studies have shown that the
learning and memory deficits of Nf1+/− mice are caused by
excessive Ras/Mapk signaling leading to hyperphosphor-
ylation of synapsin I, and subsequent enhancements in
GABA release, which in turn result in impairments in the
induction of long-term potentiation (LTP), a cellular
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mechanism of learning and memory [13, 14]. Accordingly,
a brief intervention specifically in adults with the farnesyl-
transferase inhibitor BMS 191563 [13] reversed the
biochemical, electrophysiological and behavioral pheno-
types of the Nf1+/− mice. BMS 191563 decreases the levels
of active Ras by decreasing farnesylation and therefore the
membrane associated form of this signaling molecule.
Similarly, acute treatment with a low dose of a GABAA
antagonist (picrotoxin), ineffective in controls, could also
reverse the LTP and learning deficits of adult Nf1+/− mice
[14]. Importantly, the doses of BMS 191563 and picrotoxin
used in these studies reversed the learning deficits in Nf1+/−
mice but did not change learning in wild-type control mice.
These results demonstrate that the treatments used targeted
the mechanisms specifically affected in the mutant mice.
Recent studies found that statins are a potent inhibitor of
Ras/Mapk activity in the brain. Importantly, at concen-
trations ineffective in controls, statins reversed the en-
hanced Ras activity in the brain of Nf1+/− mice, rescued
their LTP deficits, and reversed their spatial learning and
attention impairments [12]. Strikingly, recently completed
pilot clinical trials [15] uncovered suggestive evidence that
statins may also be able to reverse some cognitive deficits
in children with NF1. Although a short 12-week statin
treatment did not have a significant overall impact on the
cognition of NF1 patients, it did reverse impairments in an
object assembly test [15]. It is also worth noting that the
treatment impacted only object assembly scores of those
NF1 individuals with poor performance, while having no
effect on patients with normal performance at the start of
the trial. Currently ongoing trials with more patients and
with longer treatments may determine whether statins have
a beneficial impact on the cognition and, more importantly,
quality of life of NF1 patients. There have been reports that
suggest that NF1 patients are affected by other neurological
and psychiatric symptoms, such as higher rates of autism
and epilepsy. It will be important to determine if these and
other symptoms are also ameliorated by treatment with
statins. Interestingly, beyond NF1, a number of other
neurodevelopmental disorders also seem to be associated
with enhanced inhibition, including Down syndrome.
Elegant studies with Ts65Dn mice [16], an animal model
of Down syndrome, also revealed LTP and learning deficits
that appear to be caused by enhanced GABAergic inhibi-
tion [17, 18]. Down syndrome, a result of trisomy of
chromosome 21, is the most common genetic cause of
intellectual disability. The Ts65Dn mice include a partial
triplication of chromosome 16, the mouse homologue to
human chromosome 21. The vast majority of studies on this
genetic condition were previously focused on identifying
and studying the developmental implications of the many
genes triplicated in trisomy 21, since this disorder has a
clear onset during development. However, a recent study
[18] demonstrated that the LTP and learning impairments of
Ts65Dn mice could be reversed by manipulations that
decrease GABAergic inhibition. Chronic, but not acute,
doses of pentylenetetrazole (PTZ), picrotoxin and biloba-
lide, three different GABAA receptor antagonists, were
shown to reverse deficits in object recognition in adult
Ts65Dn mice [18]. Amazingly, these effects persisted up to
2 months following PTZ treatment; accordingly, studies of
LTP showed that PTZ-treated Ts65Dn mice demonstrated
improvements in LTP up to 3 months after the end of
treatment [18]. A recent study from another group
confirmed that a 7-week treatment with the GABAA
receptor antagonist pentylenetetrazole reversed spatial
learning deficits in adult Ts65Dn mice [19]. Altogether,
these findings suggest that treatment with GABAA receptor
antagonists leads to long-lasting effects in synaptic plastic-
ity, learning and memory in Ts65Dn mice, and they suggest
that similar treatments may also be effective in Down
syndrome. It is important to note, however, that this type of
therapeutic strategy could be problematic in the case of
neurodevelopmental disorders with increased susceptibility
for seizures. GABAA receptor antagonists may also have
negative anxiogenic effects. Thus, it may be important to
develop diagnostic tools for individualized medicine
approaches that identify individuals that could benefit from
specific therapeutic approaches, such as GABAA receptor
antagonists.
Unlike the case with Nf1+/− mice, where treatment with
picrotoxin had a more immediate effect on learning [14], in
the Ts65Dn mice this effect was delayed [18, 19]. This is
puzzling since GABAA receptor antagonists have an
immediate effect on inhibition. This unexplained delayed
therapeutic action is not unlike other psychopharmacolog-
ical effects, such as the well-characterized delayed effect of
antidepressants. One possibility is that treatment with
GABA receptor inhibitors, and the resulting lowering of
inhibitory tone, could reactivate latent developmental
plasticity processes [20, 21], and therefore lead to the
restoration of LTP and learning in the Ts65Dn mice. If this
were true, the same treatment could be used in a wide range
of conditions.
Although considerably less common than Down syn-
drome, Rubinstein-Taybi Syndrome (RTS) is another
genetic disorder also characterized by intellectual disability
and characteristic changes in physical features [22].
Mutations in several genes, including the CREB binding
protein (CBP), are known to cause this syndrome [23].
Increases in cAMP triggered by learning are thought to
activate transcription regulated by both CBP and CREB.
CBP is also known to have histone acetyltransferase
activity. Previous studies implicated CBP in transcriptional
responses required for long-term memory [24, 25]. Accord-
ingly, studies with context fear conditioning and object
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recognition showed that a mouse model of RTS (Cbp+/−
mice) has normal short-term memory, but impaired long-
term memory [26, 27]. Importantly, the memory deficits of
these mutants could be treated in adult mice with
pharmacological strategies that enhance CREB dependent
gene expression. For example, SAHA, an histone deacety-
lase (HDAC) inhibitor was shown to improve context fear
memory in Cbp+/− mice [27]. Similarly, treatments with
phospodiesterase-4 (PDE-4) inhibitors given to adult
mutants also resulted in long-term memory improvements
[26]. PDE-4 inhibitors block the breakdown of cAMP and
presumably enhance PKA-dependent activation of CREB.
Consequently, it is possible that similar treatments may also
help RTS individuals. It is important to note that both
HDAC and PDE-4 inhibitors are known to improve long-
term memory in wild-type mice. Again, clinical application
of these approaches will require a great deal of caution,
since both of these inhibitors, especially when given to
pregnant mothers or young children, may have serious side
effects.
Tuberous sclerosis complex (TSC) is another example of
a neurodevelopmental disorder where treatment of the
primary biochemical deficits in adult mice resulted in clear
improvement of cognitive phenotypes. TSC is associated
with intellectual disability, autism, epilepsy, ADHD and
specific learning disabilities [28, 29]. This disorder is
caused by heterozygous mutations in either the TSC1 or
the TSC2 genes [30, 31]. Although tubers and early onset
seizures account only partially for the variability in IQ in
TSC subjects [32], these and other developmental brain
abnormalities were traditionally thought to be the cause of
cognitive impairments [32, 33].
In mouse models of TSC, however, recent studies
demonstrated learning and memory deficits in the absence
of tubers or spontaneous seizures [34, 35]. Mechanistic
studies in mice heterozygous for a null mutation of the Tsc2
gene (Tsc2+/−) suggested that the learning and memory
deficits in these mice are caused by abnormalities in LTP
due to enhancements in mTOR signaling. The proteins
encoded by the Tsc1 and Tsc2 genes serve as a GTPase
activating protein complex (GAP) that modulates mTOR
signaling. The increase in mTOR signaling appeared to
change the threshold for the induction of the late-phase of
LTP. Conditions that normally induce only a short-lived
early-phase of LTP in controls, triggered instead an
abnormally stable LTP in Tsc2+/− mice [35]. Such inappro-
priate stabilization of plasticity may degrade the specificity
of synaptic modifications that occur during normal learn-
ing, thereby leading to memory impairments. Remarkably,
decreasing mTOR signaling in adult Tsc2+/− mice with a
brief treatment of rapamycin, an FDA-approved drug,
rescued the context discrimination, spatial learning and
LTP abnormalities of these mutants [35]. These results
demonstrated that the learning and memory impairments in
Tsc2+/− mice were not caused by irreversible developmental
deficits, and that instead they were likely due to abnormally
high mTOR signaling in adults [35].
Even though mice heterozygous for TSC genes do not
show either cortical tubers or spontaneous seizures [34, 35],
homozygous TSC mutants have a more severe phenotype
that includes seizures, neurological impairments and lethal-
ity. Importantly, these phenotypes were also rescued by
rapamycin [35–37]. Inhibitors of mTOR signaling, howev-
er, did not reverse abnormal orientation of apical dendrites
in layer V of the somatosensory cortex [36], suggesting that
full reversal of TSC neurodevelopmental phenotypes may
not be possible, or that TSC may lead to changes in
signaling that rapamycin cannot reverse.
Like TSC, mutations in PTEN (phosphatase and tensin
homolog deleted on chromosome ten) are also associated
with autism [38–40]. In addition, mutations in this gene can
lead to Lhermitte-Duclos disease (associated with intellec-
tual disability, ataxia, cerebellar ganglion cell hypertrophy
and seizures) and Cowden syndrome (a multiple hamar-
toma syndrome). PTEN regulates phosphatidylinositol-3
kinase (PI3K) upstream of TSC-mTOR signaling. Studies
with Pten mutant mice have also documented surprising
recovery of behavioral and neurological impairment in
adult animals after disease onset [41, 42]. Inhibition of
mTOR with rapamycin has been found to reduce anxiety,
improve social activity, and control seizures in mutant mice
with a neuronal-specific homozygous Pten mutation, even
when treatment was initiated in adult animals [41, 42]. The
cluster of neurological abnormalities, behavioral changes
and seizures in Pten mutant mice is significant because it is
reminiscent of phenotypes associated with autism in
patients. Importantly, brain macrocephaly, anxiety, social
impairments and epilepsy, all phenotypes commonly asso-
ciated with autism, are either partially or completely treated
with rapamycin, even when treatment is initiated in adult
mice [41, 42]. It is possible that targeting a single pathway
will not be sufficient to reverse key phenotypes, such as
brain macrocephaly, anxiety, social impairments and epi-
lepsy. Instead, a combined therapy that targets key
signaling pathways disrupted may be more efficacious.
For example, PTEN also regulates GSK-3 signaling and it
is possible that therapies that target both GSK-3 and mTOR
signaling would be more efficacious.
The PI3K/AKT/TSC pathway is a key pathway control-
ling protein synthesis and brain growth, and disruptions in
this pathway could lead to developmental abnormalities
associated with (and perhaps causing) autism [43]. Accord-
ingly, mutations in PTEN and TSC genes have been
associated with macrocephaly in humans and mice. A
treatment with rapamycin started at 10–12 weeks of age and
lasting for 4–6 weeks, reversed macrocephaly and neuronal
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hypertrophy as well as resulted in significant structural
neuroanatomical recovery in Pten mutant mice [42].
However remarkable, it is important to point out that this
recovery was not complete since some abnormalities
remained, including compression of the CA1 region. As
with the TSC mutant mice, rapamycin resulted in dramatic
improvements of already established morphological abnor-
malities, but not in complete reversal of these abnormali-
ties. Altogether the studies reviewed demonstrate that
pathological alterations in PI3K/AKT/TSC/mTOR signal-
ing result in neurodevelopmental deficits, many of which
could be reversed with pharmacological treatments in
adults.
As with PI3K/AKT/TSC/mTOR signaling disorders,
mutations in the gene causing Fragile X syndrome (FXS),
a neurodevelopmental disorder, are also associated with
mRNA translation abnormalities and autism. Additionally,
this X-linked disorder also includes learning disabilities,
intellectual disability, ADHD and epilepsy [44]. CGG
triplet repeat-expansions in the 5′ untranslated region of
the FMR1 gene are thought to lead to hypermethylation
which blocks transcription of the FMR1 gene, and a
reduction in the FMR protein (FMRP). FMRP is an RNA-
binding protein involved in the local regulation of protein
synthesis downstream of mGluR signaling, thereby con-
tributing to the control of spine morphology and synaptic
function [45]. Specifically, increased group I mGluR
signaling appears to play a central role in the pathophys-
iology of FXS, including associated cognitive dysfunction
[46, 47], since a mGluR5 germ-line heterozygous mutation
rescued a wide range of behavioral and physiological
phenotypes in the Fmr1 knockout mouse model of FXS.
This demonstrates that mGluR signaling plays an important
role in the phenotypes of these mice [46].
Remarkably, mGluR antagonists rescued defective court-
ship behavior, impaired memory in a conditioned courtship
task and CNS structural brain abnormalities in a Drosophila
model of FXS [48]. Although treatment given specifically
during development rescued abnormal courtship behavior,
memory impairments and neuroanatomical defects in
mushroom bodies in adult FXS flies, adult treatment only
rescued partially the abnormal courtship behavior and the
memory impairments. Adult treatment also did not reverse
structural brain abnormalities in mushroom bodies of adult
FXS flies. Interestingly, the same treatment with mGluR
antagonists that helped FXS flies, led to deficits in wild-
type flies, confirming the specificity of the mechanisms
targeted. These results suggest that abnormal courtship
behavior and memory impairments observed in adult
FXS flies are caused by abnormal mGluR signaling
during both development and in adulthood. Again, rescue
of the signaling deficits in either development or adulthood
resulted in significant rescue of the behavioral impairments.
Studies in mice have also provided evidence that acute
pharmacological treatment with mGluR5 antagonists in
adults ameliorated some of the phenotypes associated with
FXS, including audiogenic seizures and open field behav-
ioral abnormalities [49, 50].
Another potential treatment strategy for FXS is to block
excessive protein synthesis downstream of mGluR signal-
ing. In fact, adult treatment of FXS mutant flies with the
protein synthesis inhibitors puromycin or cycloheximide
restored memory impairments [51]. Protein synthesis
inhibitors were also effective against epileptic activity in
Fmr1 knockout mice [52]. These findings [51, 52] and
others reviewed above [35, 41, 42] indicate that disinhibited
translational control in the mature nervous system contrib-
utes to cognitive and neurological symptoms in autism-
associated genetic disorders, such as TSC and FXS.
Pilot clinical trials suggest that reversing mGluR5
signaling deficits may also ameliorate FXS phenotypes in
adult patients. For example, a pilot, open label trial
suggested that lithium seemed to improve 5 different
outcome measures in FXS individuals [53]. However, it is
difficult to interpret these findings because these results
could have been due to placebo effects unfortunately
common in clinical trials with cognitive and behavioral
outcomes [15, 54]. Similar concerns affect the interpretation
of a pilot open-label, single-dose trial of fenobam, an
mGluR5 antagonist, where a single oral dose appeared to
result in improved pre-pulse inhibition (PPI) [55]. Never-
theless, the studies in flies, mice and FXS individuals
suggest that increases in mGluR5 signaling contribute to
the FXS phenotype, and that adult interventions that
decrease these signaling abnormalities have considerable
potential in treating FXS.
Rett syndrome [56] is another X-linked developmental
genetic disorder associated with autistic phenotypes includ-
ing repetitive behaviors, impaired sociability, language and
communication problems. Motor symptoms, such as devel-
opmental delay or even difficulties in walking, spasticity,
ataxia, hypotonia, respiratory dysfunction, dystonia, chorea,
as well as intellectual disability and seizures are also
common in Rett syndrome. This disorder affects primarily
girls and is caused by mutations in a X-chromosomal gene
that encodes the transcriptional regulator MeCP2 [57]. This
protein modulates the expression of a large number of other
genes and it appears to act both as a transcription activator
and repressor [58]. Mecp2 expression is restricted to
neuronal lineage cells and becomes more pronounced with
neuronal maturation [59].
Rett syndrome mouse models have been generated with
deletions of murine Mecp2 [60–62]. The deletion of Mecp2
in male mice causes high mortality and progressive
neurological disease, including gait abnormalities, respira-
tory dysfunction, and hind limb clasping. Although milder,
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female mutant mice also show neurological impairments
that do not appreciably reduce survival. Mecp2 mutant mice
also have decreased neuronal arborization that appears to be
the cause for their lower brain volumes.
Recently, an elegant series of experiments using the Cre-
loxP genetic strategy looked at the consequences of
restoring normal Mecp2 gene function at various ages
[63]. In these experiments the Mecp2 gene was silenced
with a lox-STOP cassette that was deleted at different
developmental ages, thus restoring gene function. The
deletion was carried out with a fusion protein between the
Cre recombinase that recognizes the lox sites and a mutated
form of the ligand binding domain of the estrogen receptor
that renders Cre activity tamoxifen inducible. The analysis
of a number of phenotypes caused by the Mecp2 mutation,
including hind limb clasping, inertia, irregular breathing,
gait, and tremor, showed that these phenotypes were not
irreversible even in adults. Accordingly, restoring Mecp2
expression in mature female mutant mice, after onset of
neurological disease, reversed function to wild-type levels
and restored proper levels of neuronal plasticity. Interest-
ingly, sudden restoration of Mecp2 function actually caused
death in half of the mice treated, while a more gradual re-
expression schedule did not. This result suggests that the
dynamic (although precarious) biochemical balance estab-
lished in mutant mice had to be reversed in a progressive
gradual manner. Additionally, it is important to note that
restoration of normal Mecp2 expression only took place in
approximately 80% of cells, demonstrating that complete
reversal is not needed for significant gains in function. This
is a key result with significant repercussions for possible
future clinical studies with viral vectors where only a subset
of cells may be expected to be transfected. These
fascinating findings demonstrate that deficits caused by
loss of Mecp2 function in development do not result in
irrevocable impairments. Instead, reversing the cause for
the neurodevelopmental deficits in adults can restore
function (at least partially).
Interestingly, a common theme in many of the genetic
disorders reviewed here is a change in the ratio between
excitation and inhibition. For example, this ratio was
decreased in the neocortex of Mecp2 mutant mice [64]; in
Fragile X mice this ratio was increased due to reduced
excitatory drive to inhibitory neurons [65]. As discussed
above, both NF1 and Down syndrome mouse models
showed higher levels of inhibition but normal excitation
[13, 14, 17]. Altogether, the analyses of these and other
models [66] suggest that a change in the balance between
excitation and inhibition is an important feature of neuro-
developmental disorders [67].
What could be the reasons for this surprising rescue of
cognitive function in mouse models of neurodevelopmental
disorders? One possibility is that unlike humans, in mice
these disorders have only a minor neurodevelopmental
component. This is unlikely, since there is extensive
evidence for the involvement of the disrupted signaling
pathways in development. Additionally, in some of the
cases described (e.g. Mecp2), there was direct evidence for
developmental changes that were later reversed or amelio-
rated in adults. Another possibility is that there is far more
adult plasticity than it was previously suspected [20, 21,
68–70], and that these mechanisms are engaged in
reversing the neurodevelopmental phenotypes of these
models. It is also possible that neurodevelopmental genes
also have functions in adults (e.g., DISC1, NF1, TSC,
Fragile X, etc.) and once the primary biochemical deficit is
corrected in adults, latent neurodevelopmental mechanisms
for cellular, structural and behavioral plasticity are respon-
sible for recovery of function. Whatever the mechanism,
these studies strongly indicate that rescuing the underlying
mechanisms in adults can result in substantial improve-
ments in function. Although it is unclear whether the
dramatic rescues reviewed here will extend to humans, or
whether they will apply to other neurodevelopmental
disorders, they add considerable credibility to the dream
that one day we may have adult treatments for the many
millions of people affected by neurodevelopmental disor-
ders, such as autism.
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